This Article Full Text Full Text (PDF) Other Versions of this Article: MCB.00757-06v1 27/5/1934    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shattuck, D. L. Articles by Sweeney, C. Search for Related Content PubMed PubMed Citation Articles by Shattuck, D. L. Articles by Sweeney, C.

LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 Synergy

David L. Shattuck, Jamie K. Miller, Melanie Laederich, Melanie Funes, Heidi Petersen, Kermit L. Carraway III, and Colleen Sweeney^*

UC Davis Cancer Center, Sacramento, California 95817

Received 1 May 2006/ Returned for modification 16 June 2006/ Accepted 8 December 2006

The Met receptor tyrosine kinase regulates a complex array of cellular behaviors collectively known as "invasive growth." While essential for normal development and wound repair, this program is frequently co-opted by tumors to promote their own growth, motility, and invasion. Met is overexpressed in a variety of human tumors, and this aberrant expression correlates with poor patient prognosis. Previous studies indicate that Met receptor levels are governed in part by cbl-mediated ubiquitination and degradation, and uncoupling of Met from cbl-mediated ubiquitination promotes its transforming activity. Here we describe a novel mechanism for Met degradation. We find that the Met receptor interacts with the transmembrane protein LRIG1 independent of hepatocyte growth factor (HGF) stimulation and that LRIG1 destabilizes the Met receptor in a cbl-independent manner. Overexpression of LRIG1 destabilizes endogenous Met receptor in breast cancer cells and impairs their ability to respond to HGF. LRIG1 knockdown increases Met receptor half-life, indicating that it plays an essential role in Met degradation. Finally, LRIG1 opposes Met synergy with the ErbB2/Her2 receptor tyrosine kinase in driving cellular invasion. We conclude that LRIG1 is a novel suppressor of Met function, serving to regulate cellular receptor levels by promoting Met degradation in a ligand- and cbl-independent manner.

Published ahead of print on 18 December 2006.

D.L.S. and J.K.M. contributed equally to this work.

Present address: Oregon Health Sciences University, Portland, OR 97239.

This article has been cited by other articles:

• Zhao, H., Tanegashima, K., Ro, H., Dawid, I. B. (2008). Lrig3 regulates neural crest formation in Xenopus by modulating Fgf and Wnt signaling pathways. Development 135: 1283-1293 [Abstract] [Full Text]  
• Shattuck, D. L., Miller, J. K., Carraway, K. L. III, Sweeney, C. (2008). Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells. Cancer Res. 68: 1471-1477 [Abstract] [Full Text]  
• Ledda, F., Bieraugel, O., Fard, S. S., Vilar, M., Paratcha, G. (2008). Lrig1 Is an Endogenous Inhibitor of Ret Receptor Tyrosine Kinase Activation, Downstream Signaling, and Biological Responses to GDNF. J. Neurosci. 28: 39-49 [Abstract] [Full Text]